Oculis Holding AG (OCS)
(Real Time Quote from BATS)
$17.91 USD
+0.03 (0.17%)
Updated Nov 4, 2024 09:38 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OCS 17.91 +0.03(0.17%)
Will OCS be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for OCS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OCS
Oculis Holding AG (OCS) Moves 7.9% Higher: Will This Strength Last?
Oculis Holding AG (OCS) Surges 8.2%: Is This an Indication of Further Gains?
OCS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Oculis Holding AG (OCS) Reports Q2 Loss, Misses Revenue Estimates
IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Lags Revenue Estimates
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
Other News for OCS
Oculis Holding Gains ‘Buy’ Rating Amid Promising Clinical Trial Advancements and Pipeline Potential
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials
Oculis accelerates patient enrollment for both Phase 3 DIAMOND trials
Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award
Oculis to Present at Upcoming September Investor Conferences